Outlicensing opportunities to BECOME A LEADER IN ALLERGY.
ASIT biotech is a Belgian clinical stage biopharmaceutical company.
ASIT biotech’s mission is to lead an evolution in allergy therapeutics by creating a new generation of highly effective and efficient immunotherapy options for environmental and food allergy. Our goal is to generate breakthrough treatments that deliver rapid, recognizable improvement in the quality of life for allergy patients, within weeks rather than months or years following treatment initiation.
Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient acceptance, compliance and real-life effectiveness.
ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ (phase 3) and house dust mite: hdm-ASIT+™ (ready for phase 1), and food allergies (peanut allergy: pnt-ASIT+™(ready for phase 1)) that could significantly expand the current immunotherapy market.
ASIT is currently looking for global or regional partners for its lead product, gp-ASIT+™, addressing the allergy of grass pollen, which had a successful phase III and has just started a second (confirmatory) Phase III with results expected in December 2019.
Two other products, addressing the allergies to house dust mite and peanuts are ready to start a Phase I/II and are also looking for development and/or financial partners.
The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of protein-based allergies. Therefore, many other ASIT products for respiratory and food allergy are candidate to be developed provided the right level of partnership/finance is found.
More info on www.asitbiotech.com